Every material Form 8-K MetaVia Inc. has filed with the SEC since October 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MetaVia said interim Part 3B data from its Phase 1 trial of DA-1726 showed a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss after 16 weeks, with 15 DA-1726-treated and four placebo participants in the interim analysis. The company said the results support a planned 48-week Phase 2 study in up to 150 patients with MetALD and ALD, targeted to begin in the second half of 2027, but the sample is small and full data are not due until the first quarter of 2027.
Liver fat (MRI-PDFF) fell 68% placebo-adjusted at Day 109 (p<0.001); all five participants with baseline steatosis fell below 5%
Body weight fell 13.5% placebo-adjusted (p<0.001); HbA1c fell 0.24 percentage points versus placebo (p=0.006) in participants without diabetes
One serious adverse event, severe vomiting, was considered possibly related to treatment; the participant recovered
Full Part 3A and 3B data expected in Q1 2027; Phase 2 study targeted to start in 2H 2027
MetaVia Inc. announced that an abstract on Phase 1 clinical trial data for DA-1726, a dual GLP-1 and glucagon receptor agonist, was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver, Colorado. The filing is an update on a clinical program and contains no financial results, guidance, or transaction terms.
Presentation is scheduled for November 4, 2026, at 1:35 pm MT at the Hilton Denver City Center.
Chief Medical Officer Sarah Browne, M.D., will present the data.
The presentation title cites reduction in MRI-PDFF and weight loss with relative preservation of lean mass in a randomized placebo-controlled trial.
A poster will be posted on the MetaVia website after the presentation.
MetaVia Inc. named Sarah Browne, M.D. as its Chief Medical Officer, effective October 12, 2026, as disclosed in an 8-K filed October 13, 2026. The company said she will support development of DA-1726 ahead of an anticipated fourth quarter 2026 topline data readout from Part 3 of a Phase 1 trial.
Appointment effective October 12, 2026; announced in a press release dated October 13, 2026
Dr. Browne previously led clinical development of pemvidutide at Altimmune, Inc., through Phase 2
Company expects topline data from Part 3 of the Phase 1 DA-1726 trial, testing 48 mg and 64 mg doses, in Q4 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MetaVia Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →